San Diego-based Cidara Therapeutics gained fast-track status from the U.S. Food and Drug Administration for its lead drug candidate aimed at preventing invasive fungal infections, the company announced Sept. 25.
La Jolla-based Equillium intends to raise $86 million through an initial public offering, according to recently filed U.S. Securities and Exchange Commission paperwork.
La Jolla Vein Care – which treats vein disease and disorders – recently doubled its clinic space.
Kevin Gunderson was employee No. 7 of 6,000 at Illumina. He led the company’s advanced research group for almost 18 years, helping create its first $1 billion product line.
MEDICINE: Extending Lives, Cutting Waste Are Part of Goals
Epic Sciences’ pitch: greater certainty. The company’s portfolio of tests guide cancer doctors deciding on a treatment path, including a test on the market for advanced prostate cancer.
Medications can help manage symptoms of Huntington’s disease. But invariably sufferers are robbed of mental and physical abilities.
The U.S. Senate on Sept. 17 passed bipartisan legislation to combat the opioid epidemic. For at least one San Diego biotech, a notable measure was missing.
The U.S. Food and Drug Administration didn’t find new safety concerns after reexamining Acadia Pharmaceutical’s drug to treat hallucinations and delusions caused by Parkinson’s disease.
San Diego-based Alliance Healthcare Foundation established has a new $2 million fund with the San Diego Foundation. That money will be split between the Multicultural Health Foundation and Somali Family Services.
Laura Shawver — perhaps best known as the CEO of Synthorx — launched the Clearity Foundation after her own experience with ovarian cancer.
United Therapeutics Corporation gained North American licensing rights to a lung disease drug from San Diego’s Samumed in a deal announced Sept. 17.
In 2000, the cost to sequence a genome stood at $100 million.
ViaCyte, a San Diego stem cell therapy biotech, has teamed up with a Massachusetts gene-editing company to take on diseases like diabetes.
San Diego-based Sherpa Clinical Packaging has been acquired by PCI Pharma Services under a deal announced Sept. 11 in which terms were not disclosed.